Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Treatment for neurofibromatosis type 1 may involve surgery, radiation, chemotherapy, or other methods. In some cases, doctors may take a “wait and see” approach. Neurofibromatosis type 1 (NF1), ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable to complete surgical resection are indicated in the approval. Mirdametinib ...

Neurofibromatosis type 1 (NF1) is the most common of the three types of neurofibromatosis and is also one of the most common inherited neurological disorders, affecting about 1 in 3,000 people ...

Selumetinib received FDA approval for adults with NF1 and symptomatic, inoperable plexiform neurofibromas, based on the phase 3 KOMET trial results. The KOMET trial showed a 20% objective response ...

Benign tumors can grow along nerves anywhere in the body, causing complications such as pain, mobility issues, and psychosocial issues. Neurofibromatosis 1-associated plexiform neurofibromas (NF1-PN) ...

Learning that your child has neurofibromatosis type 1 (NF1) comes with a range of emotions and practical concerns. While many people diagnosed with NF1 will have a normal life expectancy, the ...

Neurofibromatosis type 1 (NF1) is a genetically inherited disorder that manifests in a broad spectrum of clinical features including dermatological, neurological, skeletal and notably, ocular ...